<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04753034</url>
  </required_header>
  <id_info>
    <org_study_id>TER101-AD-201</org_study_id>
    <nct_id>NCT04753034</nct_id>
  </id_info>
  <brief_title>Study of TER-101 Topical Ointment in Subjects With Atopic Dermatitis</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Vehicle-Controlled, Phase 2 Study of TER-101 Topical Ointment to Assess Efficacy and Safety in Subjects With Mild to Moderate Atopic</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teres Bio, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teres Bio, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 2 study will assess efficacy, safety, and tolerability of TER-101 ointment and&#xD;
      vehicle twice daily for 28 days in adult and adolescent subjects with mild to moderate atopic&#xD;
      dermatitis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 18, 2021</start_date>
  <completion_date type="Actual">May 3, 2021</completion_date>
  <primary_completion_date type="Actual">May 3, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in EASI from baseline at Day 29</measure>
    <time_frame>30 days</time_frame>
    <description>EASI = Eczema Area and Severity Index, EASI combines the assessment of the severity of lesions and the the numerical area affected into a single total score in the range 0 (no disease) to 72 (maximal disease). To calculate the EASI, the sum of the severity rating (0 to 3 with 3 being the most severe) for erythema, induration, lichenifcation, excoriation are multiplied with value of the area affected and with the percentage of the four body areas.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in EASI over time</measure>
    <time_frame>15 - 30 days</time_frame>
    <description>EASI combines the assessment of the severity of lesions and the area affected into a single total score in the range 0 (no disease) to 72 (maximal disease). To calculate the EASI, the sum of the severity rating (0 to 3 with 3 being the most severe) for erythema, induration, lichenifcation, excoriation are multiplied with the numerical value of the area affected and with the percentage of the four body areas.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in IGA from baseline over time</measure>
    <time_frame>15 - 30 days</time_frame>
    <description>IGA = Investigator Global Assessment (Scale 0 - 4) 0 = Clear&#xD;
= Almost Clear&#xD;
= Mild&#xD;
= Moderate&#xD;
= Severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in itch over time</measure>
    <time_frame>15 - 30 days</time_frame>
    <description>The WI-NRS asks subjects to report their worst itch (maximal intensity) during the last 24 hours on an 11-point NRS, ranging from 0 = &quot;no itch at all&quot; to 10 = &quot;worst itch you can imagine&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability of TER-101 ointment vs. vehicle in subjects with AD</measure>
    <time_frame>30 days</time_frame>
    <description>Sum of erythema, itch, and burning at the time of visit compared to baseline measured on a 0 - 3 scale for each component.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Adverse Events (AEs)</measure>
    <time_frame>30 days</time_frame>
    <description>Comparison by treatment group of reported adverse events (MedRA coded).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>TER-101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BID (twice daily) application</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle ointment, BID (twice daily) application</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TER-101</intervention_name>
    <description>Active Comparator</description>
    <arm_group_label>TER-101</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>Placebo Comparator</description>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adolescent or adult subject aged 12 - 65 years.&#xD;
&#xD;
          -  Overall IGA score of 2 (mild) or 3 (moderate) at baseline on a 5-point IGA&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  AD with known hypersensitivity to excipients of TER-101 Ointment&#xD;
&#xD;
          -  Subjects who are immunocompromised&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Teres Bio site 05</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85255</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teres Bio Site 04</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teres Bio Site 12</name>
      <address>
        <city>North Miami Beach</city>
        <state>Florida</state>
        <zip>33162</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teres Bio Site 10</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teres Bio Site 02</name>
      <address>
        <city>Clarksville</city>
        <state>Indiana</state>
        <zip>47129</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teres Bio Site 01</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teres Bio site 09</name>
      <address>
        <city>Saint Joseph</city>
        <state>Missouri</state>
        <zip>64506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teres Bio Site 08</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teres Bio Site 11</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teres Bio Site 03</name>
      <address>
        <city>College Station</city>
        <state>Texas</state>
        <zip>77845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teres Bio Site 06</name>
      <address>
        <city>Pflugerville</city>
        <state>Texas</state>
        <zip>78660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teres Bio Site 07</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 21, 2021</study_first_submitted>
  <study_first_submitted_qc>February 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2021</study_first_posted>
  <last_update_submitted>May 11, 2021</last_update_submitted>
  <last_update_submitted_qc>May 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

